Moderna (MRNA) Q4 Revenue Beats, Chief Medical Officer to Depart

Moderna (NASDAQ: MRNA) reported Q4 EPS of ($0.69), $0.34 worse than the analyst estimate of ($0.35). Revenue for the quarter came in at $571 million versus the consensus estimate of $279.41 million.

2021 Vaccine Manufacturing: Raises lower end of global manufacturing plan for 2021 from 600 million doses to 700 million doses; manufacturing is still working to supply up to 1 billion doses for 2021

2022 Vaccine Manufacturing: Based on the high demand from around the world for our COVID-19 vaccine and variant-based boosters, making new capital investments to increase capacity up to 1.4 billion doses in 2022

• Moderna’s Chief Medical Officer (CMO), Tal Zaks, M.D., Ph.D., will be leaving the Company in late September after six years of service. The Company has retained Russell Reynolds to recruit for a new CMO with global and commercial experience as the Company scales up the launch of its COVID-19 Vaccine and prepares to file several biologics license applications (BLAs) over the next few years.

For earnings history and earnings-related data on Moderna (MRNA) click here.

You May Also Be Interested In

• Gilead Sciences (GILD) Misses Q1 EPS by 288c
• L3Harris Technologies (LHX) Tops Q1 EPS by 15c; raises guidance
• Gaming and Leisure Properties (GLPI) Misses Q1 EPS by 6c